Filing Details

Accession Number:
0001104659-24-066985
Form Type:
13G Filing
Publication Date:
2024-05-30 20:00:00
Filed By:
Forsakringsaktiebolaget Avanza Pension
Company:
China Sxt Pharmaceuticals Inc. (NASDAQ:SXTC)
Filing Date:
2024-05-31
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Forsakringsaktiebolaget Avanza Pension 30,679 7 8 30 30,679 5,42 %
Filing

 

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

 

 

SCHEDULE 13G

(Amendment no. 2)

 

(Rule 13d-102)

 

Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments

Thereto Filed Pursuant to § 240.13d-2.

 

Under the Securities Exchange Act of 1934

 

China SXT Pharmaceuticals Inc

(Name of Issuer)

 

          COMMON STOCK, PAR VALUE $0.08PER SHARE          

(Title of Class of Securities)

 

          G2161P140          

(CUSIP Number)

 

                    May 30, 2024                    

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

xRule 13d-1(b)
¨Rule 13d-1(c)
¨Rule 13d-1(d)

 

 

 

Page 1 of 6 Pages

 

 

 

 

CUSIP No.: G2161P140SCHEDULE 13GPage 2 of 6 Pages

 

1)

NAME OF REPORTING PERSON

 

Forsakringsaktiebolaget Avanza Pension

2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)       ¨

(b)       ¨

3)

SEC USE ONLY

 

 

4)

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Stockholm, Sweden

  NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5)

SOLE VOTING POWER

 

30,679

6)

SHARED VOTING POWER

 

 

7)

SOLE DISPOSITIVE POWER

 

 

8)

SHARED DISPOSITIVE POWER

 

30,679

9)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

30,679

10)

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

¨

11)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

5,42 %

12)

TYPE OF REPORTING PERSON

 

FI

         

 

CUSIP No.: G2161P140SCHEDULE 13GPage 3 of 6 Pages

 

Item 1(a).Name of Issuer:

 

China SXT Pharmaceuticals Inc

 

Item 1(b).Address of Issuer’s Principal Executive Offices:

 

178 Taidong Road North

TAIZHOU, JNG, 225300

China

 

Item 2(a).Name of Person Filing:

 

Forsakringsaktiebolaget Avanza Pension

 

Item 2(b).Address of Principal Business Office or, if None, Residence:

 

Box 1399

STOCKHOLM, 11139

SWEDEN

 

Item 2(c).Citizenship:

 

Forsakringsaktiebolaget Avanza Pension is a company organized under the laws of Sweden

 

Item 2(d).Title of Class of Securities:

 

Common Stock, Par Value $0.08 per share

 

Item 2(e).CUSIP Number:  G2161P140

 

Item 3.If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

 

  (a) ¨ Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o)

 

  (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)

 

  (c) ¨ Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)

 

  (d) ¨ Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)

 

  (e) ¨ Investment Adviser in accordance with § 240.13d-1(b)(1)(ii)(E)

 

  (f) ¨ Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)

 

  (g) ¨ Parent Holding Company or control person in accordance with §240.13d-1(b)(1)(ii)(G)

 

  (h) ¨ Savings Association as defined in §3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)

 

  (i) ¨ Church plan that is excluded from the definition of an investment company under §3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)

 

  (j) x A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J)

 

  (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K)

 

 

CUSIP No.: G2161P140SCHEDULE 13GPage 4 of 6 Pages

 

Item 4.Ownership.

 

(a)Amount beneficially owned:  30,679

 

(b)Percent of class: 5,42 %

 

(c)Number of shares as to which such person has:

 

(i)Sole power to vote or to direct the vote:  30,679

 

(ii)Shared power to vote or to direct the vote:  None

 

(iii)Sole power to dispose or to direct the disposition of:  None

 

(iv)Shared power to dispose or to direct the disposition of: 30,679

 

Number and Percentage
of Shares Beneficially Owned
  Date
5,42 % / 30,679  May 30, 2024

 

Item 5.Ownership of Five Percent or Less of a Class.

 

Not applicable

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

 

CUSIP No.: G2161P140SCHEDULE 13GPage 5 of 6 Pages

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

 

Not applicable

 

Item 8.Identification and Classification of Members of the Group.

 

Not applicable

 

Item 9.Notice of Dissolution of Group.

 

Not applicable

 

 

CUSIP No.: G2161P140SCHEDULE 13GPage 6 of 6 Pages

 

Item 10.Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to a Swedish insurance company is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution. I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

 

SIGNATURE

 

After reasonable inquiry and to the best knowledge and belief of the undersigned, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

 

May 31, 2024  
   
   
   
   
   
Joakim Lomell / Middle Office  
Name/Title